Trial Profile
A retrospective study evaluating steroid-sparing effect of Tocilizumab and Abatacept in Patients with Giant Cell Arteritis when compared to standard glucocorticoid (GC) treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary)
- Indications Giant cell arteritis
- Focus Pharmacodynamics; Therapeutic Use
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 14 Jul 2018 New trial record